[Ad hoc announcement pursuant to Art. 53 LR] Roche: Changes in the Board of Directors and the Corporate Executive Committee

Board of DirectorsBasel, 12 December 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that at its December meeting, the Board of Directors of Roche Holding Ltd has approved to propose the following changes at the Annual General Meeting on 14 March 2023:As previously announced in July 2022, Christoph Franz has decided not to seek re-election as Chairman. The Board of Directors will propose Severin Schwan as the new Chairman at the Annual General Meeting in 2023, and has appointed Thomas Schinecker as the new Roche Group CEO effective 14 March 2023.The Board of Directors will proposeMark Schneider, CEO of Nestle S.A., andProf. Akiko Iwasaki, Sterling Professor of Immunobiology and Molecular, Cellular and Developmental Biology at Yale University, and Howard Hughes Medical Institute Investigator, for election as new Board members at the Annual General Meeting in 2023. Christoph Franz: “I am very pleased that we can propose two exceptional people in business and in science for election to the Board of Directors.”The following persons are recommended for election to the Board of Directors:NameBoard Member since Dr. Severin Schwan 2013, new as Chairman Andr é Hoffmann 1996 Dr. J örg Duschmale 2020 Dr. Patrick Frost 2020 Anita Hauser 2017 Prof. Dr. Richard P. Lifton 2015Dr. Jemilah Mahmood2022 Bernard Poussot 2015 Dr. Claudia S üssmuth Dyckerhoff 2016 Dr. Mark Schneider New Prof. Dr. Akiko Iwasaki NewAnnette Luther, Secretary to the Board of Directors, will be appoint...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news